MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna exceeded Q3 earnings expectations with 38 cents EPS versus an estimated loss of $1.10, driven by 29.2% revenue growth to $1.31 billion from international COVID-19 vaccine sales. The company raised its 2026 revenue growth target to 15-25% and reduced R&D spending plans to $2.7 billion. The stock surged in pre-market trading, with year-to-date gains exceeding 700%.